Vanda’s Nereus reduces semaglutide-induced vomiting by 27% in Phase III trial
VNDA•Vanda Pharmaceuticals said Phase III results showed Nereus reduced semaglutide-induced vomiting by 27%. The company plans to discuss the results with the FDA and seek the additional use through a supplemental New Drug Application.
1. Phase III results
Vanda Pharmaceuticals announced positive Phase III results for Nereus (tradipitant) to prevent vomiting associated with GLP-1 therapy. The treatment significantly reduced vomiting versus placebo, including frequent multiday and extreme vomiting, and was generally well tolerated with no new safety signals reported.
2. Next steps
Vanda plans FDA discussions and a supplemental New Drug Application seeking the additional use.
